From: Clinicopathologic features and responses to radiotherapy of myeloid sarcoma
Characteristics | Complete response (No. of patients) | Partial response and stable disease (No. of patients) | Complete response rate | Crude odds ratio | 95% Confidence interval | P-value* |
---|---|---|---|---|---|---|
BED dose | Â | Â | Â | Â | Â | Â |
≥22 Gy | 3 | 4 | 43% | 4.44 | 0.62-32.07 | 0.14 |
<22Â Gy | 10 | 3 | 77% | 1 (Referent) | Â | Â |
Underlying disease | Â | Â | Â | Â | Â | Â |
Non-AML | 3 | 4 | 43% | 4.44 | 0.62-32.07 | 0.17 |
AML | 10 | 3 | 77% | 1 (Referent) | Â | Â |
Age | Â | Â | Â | Â | Â | Â |
≥50 y | 3 | 5 | 37.5% | 8.33 | 1.03-67.14 | 0.06 |
<50 y | 10 | 2 | 83.3% | 1 (Referent) | Â | Â |
Gender | Â | Â | Â | Â | Â | Â |
Female | 5 | 4 | 55.6% | 2.13 | 0.33-13.81 | 0.64 |
Male | 8 | 3 | 72.7% | 1 (Referent) | Â | Â |
Cytogenetics | Â | Â | Â | Â | Â | Â |
Abnormal | 6 | 4 | 60% | 1.56 | 0.24-9.91 | 1 |
Normal | 7 | 3 | 70% | 1 (Referent) | Â | Â |
Previous BMT before RT | Â | Â | Â | Â | Â | Â |
Yes | 6 | 0 | 100% | NA | NA | 0.05 |
No | 7 | 7 | 50% | 1 (Referent) | Â | Â |
BM involvement at GS RT | Â | Â | Â | Â | Â | Â |
Yes | 8 | 5 | 61.5% | 1.56 | 0.22-11.37 | 1 |
No | 5 | 2 | 71% | 1 (Referent) | Â | Â |